Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00732940 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)
A Phase 2 study, sponsored by Human Genome Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT00732940 is a Phase 2 study that was terminated before completion, run by Human Genome Sciences. The registered enrollment target is 56 participants.
The verdict
NCT00732940, a Phase 2 study, was terminated before completion, sponsored by Human Genome Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and tolerability of repeated subcutaneous (SC) doses of belimumab in subjects with SLE.
Interventions
- DRUG Belimumab 100 mg SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2008-10 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00732940
The ClinicalTrials.gov registry entry for NCT00732940 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Human Genome Sciences, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Belimumab 100 mg SC is the first listed.
NCT00732940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00732940 about?
NCT00732940 is a clinical study titled "Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)". The purpose of this study is to test the safety and tolerability of repeated subcutaneous (SC) doses of belimumab in subjects with SLE.
What is the current status of trial NCT00732940?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2008-10. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00732940?
The interventions under investigation include: Belimumab 100 mg SC (DRUG).
Who is sponsoring clinical trial NCT00732940?
This trial is sponsored by Human Genome Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.